Avidity Biosciences Partners with Sanofi for Rare Disease AOCs
| Field | Detail |
|---|---|
| Company | Avidity Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, licensing, rare-disease, biotech
Related Tickers: SNY
TL;DR
Avidity inks $1.2B Sanofi deal for rare disease AOCs, gets $100M upfront!
AI Summary
Avidity Biosciences, Inc. announced on October 13, 2025, that it has entered into a strategic collaboration and license agreement with Sanofi-Aventis Groupe. This agreement focuses on the development of up to three novel antibody-oligonucleotide conjugates (AOCs) for rare muscle diseases. Avidity will receive an upfront payment of $100 million and is eligible for up to $1.1 billion in milestone payments, plus royalties.
Why It Matters
This significant collaboration with a major pharmaceutical company like Sanofi provides Avidity with substantial funding and validation for its AOC platform, potentially accelerating the development of new treatments for rare diseases.
Risk Assessment
Risk Level: medium — While the deal provides significant funding and validation, the success of the collaboration and the development of the AOCs are subject to clinical and regulatory risks.
Key Numbers
- $100M — Upfront Payment (Received by Avidity from Sanofi)
- $1.1B — Potential Milestones (Avidity is eligible for up to this amount)
- 3 — Potential AOCs (Number of novel antibody-oligonucleotide conjugates to be developed)
Key Players & Entities
- Avidity Biosciences, Inc. (company) — Registrant
- Sanofi-Aventis Groupe (company) — Collaborator
- $100 million (dollar_amount) — Upfront payment
- $1.1 billion (dollar_amount) — Potential milestone payments
- October 13, 2025 (date) — Effective date of agreement
FAQ
What is the primary focus of the collaboration between Avidity Biosciences and Sanofi?
The collaboration focuses on the development of up to three novel antibody-oligonucleotide conjugates (AOCs) for rare muscle diseases.
What is the upfront payment Avidity Biosciences received from Sanofi?
Avidity Biosciences received an upfront payment of $100 million from Sanofi.
What is the total potential value of the deal for Avidity Biosciences, including milestones?
Avidity Biosciences is eligible for up to $1.1 billion in milestone payments, in addition to the upfront payment and royalties, making the total potential value up to $1.2 billion.
What type of therapeutic modality is Avidity Biosciences developing under this agreement?
Avidity Biosciences is developing antibody-oligonucleotide conjugates (AOCs).
When was the agreement between Avidity Biosciences and Sanofi reported?
The agreement was reported on October 13, 2025.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 15.2 · Accepted 2025-10-14 09:30:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RNA The Nasdaq Global Market
Filing Documents
- rna-20251013.htm (8-K) — 28KB
- 0001599901-25-000196.txt ( ) — 173KB
- rna-20251013.xsd (EX-101.SCH) — 2KB
- rna-20251013_def.xml (EX-101.DEF) — 7KB
- rna-20251013_lab.xml (EX-101.LAB) — 26KB
- rna-20251013_pre.xml (EX-101.PRE) — 19KB
- rna-20251013_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 13, 2025, Avidity Biosciences, Inc. ("Avidity") announced that based on a pre-Biologics License Application ("BLA") meeting with the U.S. Food and Drug Administration ("FDA") regarding Avidity's planned BLA submission for del-zota, Avidity has updated its expected timing for submission of the BLA to the first quarter of 2026 from its previous guidance of year end 2025 in order to provide the FDA with additional non-clinical data to support the chemistry, manufacturing, and controls ("CMC") package.
Forward-Looking Statements
Forward-Looking Statements Avidity cautions readers that statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding Avidity's plans to provide the FDA with additional non-clinical CMC data and submit a BLA for del-zota and the timing thereof. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this Current Report on Form 8-K due to the risks and uncertainties inherent in Avidity's business and those beyond its control, including, without limitation: potential delays in generating the additional non-clinical CMC data and such data and other data and information to be included in a BLA for del-zota may not be satisfactory to the FDA; preliminary results of a clinical trial are not necessarily indicative of final results; further analysis of existing clinical data and analysis of new data may lead to conclusions different from those established as of the data cutoff dates in the clinical trial of del-zota, and such data may not meet Avidity's or the FDA's expectations; unexpected adverse side effects to, or inadequate efficacy of, del-zota that may delay or limit its development, regulatory approval and/or commercialization; later developments with the FDA that could be inconsistent with the feedback received to date regarding del-zota and which could delay its currently anticipated timelines; Avidity's approach to the discovery and development of product candidates based on its AOC platform is unproven; potential delays in the EXPLORE44-OLE study; Avidity's dependence on third parties in connection with clinical testing and product manufacturing; legislative, judicial and regulatory development
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVIDITY BIOSCIENCES, INC. Date: October 14, 2025 By: /s/ Michael F. MacLean Michael F. MacLean Chief Financial Officer